

THE UNIVERSITY OF MICHIGAN

Approved by the Regents

March 20, 2008

REGENTS COMMUNICATION

ACTION REQUEST

Subject: Subcontract Agreements between the University of Michigan and Sarcoma Alliance for Research through Collaboration

Action Requested: Authorization to enter into Agreements

Preamble:

A conflict of interest situation was identified by DRDA while reviewing the Proposal Approval Form that then triggered a review by the Medical School's Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was developed by the committee and agreed to by the parties involved in this agreement.

This proposed agreement falls under the State of Michigan Conflict of Interest Statute because Dr. Laurence Baker is both an employee of the University and President of the Sarcoma Alliance for Research through Collaboration (SARC). The law permits the University to enter into such an Agreement provided it is disclosed to the executive officers and approved in advance by a 2/3 vote of the Regents of the University of Michigan.

Background:

Dr. Laurence Baker, Professor of Internal Medicine, Division of Hematology/Oncology and Director for Clinical Research, Comprehensive Cancer Center, is the Co-Founder, Executive Director, President and Director of SARC, a non-profit research corporation located in Ann Arbor. SARC is funded primarily by contracts and gifts. Dr. Baker receives no compensation from SARC and has no financial interest in SARC.

Nature of the Agreement:

SARC has entered into a contract with Hoffman-La Roche Ltd. which includes financial support and a supply of the pharmaceutical drug R1507, which will be used to support clinical trials that will be funded by SARC and conducted at major cancer centers including the University of Michigan. The University's conduct of the clinical trials will be under the direction of Dr. Scott Schuetze, Clinical Assistant Professor of Internal Medicine, Division of Hematology/Oncology, who has no proprietary or other interest in SARC.

Terms of the Agreement:

The terms of the proposed Agreements are acceptable and conform to University policy. The amount of the subcontract to the University is \$207,813. The period of performance is 5 years. Human subject approval will be obtained prior to commencement of this study. Dr. Baker plays no role with regard to the University's performance of these Agreements and receives no remuneration from them.

Impact of the Agreement:

This Agreement will enable the University to participate in an important clinical research effort to determine if activity of the R1507 antibody in subjects with recurrent sarcomas warrants further study.

Recommendation:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the agreement conforms to standard University practices, I recommend that the Board of Regents approve of the University's entering into this agreement with the Sarcoma Alliance for Research through Collaboration.

Respectfully submitted,



Stephen R. Forrest
Vice President for Research

March 2008